{"altmetric_id":3238362,"counts":{"readers":{"mendeley":3,"citeulike":0,"connotea":0},"total":{"posts_count":1},"wikipedia":{"unique_users_count":1,"unique_users":["en:757797"],"posts_count":1}},"citation":{"abstract":"To evaluate the literature examining the efficacy of angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) for migraine prophylaxis.","abstract_source":"pubmed","altmetric_jid":"4f6fa5e63cf058f610005728","authors":["Barry J Gales","Emilee K Bailey","Ashley N Reed","Mark A Gales"],"doi":"10.1345\/aph.1m312","first_seen_on":"2015-02-02T16:25:17+00:00","issns":["1542-6270"],"journal":"Annals of Pharmacotherapy","last_mentioned_on":1336069194,"links":["http:\/\/dx.doi.org\/10.1345\/aph.1M312","http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/20086184"],"pdf_url":"http:\/\/aop.sagepub.com\/content\/44\/2\/360.full.pdf","pmid":"20086184","publisher_subjects":[{"name":"Pharmacology And Pharmaceutical Sciences","scheme":"era"}],"scopus_subjects":["Medicine","Health Sciences"],"subjects":["pharmacology","drugtherapy"],"title":"Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for the prevention of migraines.","type":"article","mendeley_url":"http:\/\/www.mendeley.com\/research\/angiotensinconverting-enzyme-inhibitors-angiotensin-receptor-blockers-prevention-migraines"},"altmetric_score":{"score":3,"score_history":{"1y":0,"6m":0,"3m":0,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":3},"context_for_score":{"all":{"total_number_of_other_articles":3630679,"mean":4.9289340563991,"rank":816177,"this_scored_higher_than_pct":63,"this_scored_higher_than":2292006,"rank_type":"exact","sample_size":3630679,"percentile":63},"similar_age_3m":{"total_number_of_other_articles":94336,"mean":8.1334677479199,"rank":24616,"this_scored_higher_than_pct":72,"this_scored_higher_than":68633,"rank_type":"exact","sample_size":94336,"percentile":72},"this_journal":{"total_number_of_other_articles":1205,"mean":3.0222624584718,"rank":300,"this_scored_higher_than_pct":64,"this_scored_higher_than":783,"rank_type":"exact","sample_size":1205,"percentile":64},"similar_age_this_journal_3m":{"total_number_of_other_articles":15,"mean":4.7642857142857,"rank":8,"this_scored_higher_than_pct":46,"this_scored_higher_than":7,"rank_type":"exact","sample_size":15,"percentile":46}}},"demographics":{"users":{"mendeley":{"by_status":{"Researcher":1,"Student  > Bachelor":1,"Professor":1},"by_discipline":{"Medicine and Dentistry":2,"Unspecified":1}}}},"posts":{"wikipedia":[{"title":"Angiotensin II receptor antagonist","url":"http:\/\/en.wikipedia.org\/?diff=prev&oldid=490505610#altmetric_citation_19","license":"public","citation_ids":[3238362],"posted_on":"2012-05-03T18:19:54+00:00","summary":"Angiotensin II receptor antagonists, also known as angiotensin receptor blockers (ARBs), AT1-receptor antagonists or sartans, are a group of pharmaceuticals that modulate the renin-angiotensin-aldosterone system.","page_url":"http:\/\/en.wikipedia.org\/?curid=757797","wiki_lang":"en","author":{"name":"LeadSongDog","url":"http:\/\/en.wikipedia.org\/wiki\/User:LeadSongDog"}}]}}